Mirum Pharmaceuticals ((MIRM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mirum Pharmaceuticals is conducting a Phase 3 clinical study titled ‘Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants With Cholestatic Pruritus.’ The study aims to assess the safety and effectiveness of maralixibat in treating pruritus associated with cholestatic liver disease, a condition with limited treatment options.
The intervention being tested is maralixibat, an oral solution designed to alleviate pruritus in patients with cholestatic liver disease. Participants will receive maralixibat or a placebo in a structured dosage regimen over a period of up to 39 weeks.
The study employs a randomized, parallel intervention model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose is to evaluate treatment efficacy.
The study began on August 8, 2024, with primary completion expected by July 16, 2025. The last update was submitted on July 16, 2025, indicating ongoing recruitment and study progress.
This study update could positively influence Mirum Pharmaceuticals’ stock performance by bolstering investor confidence in the company’s pipeline. The outcome may also impact competitors in the cholestatic liver disease treatment market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.